Development of Frailty Prevention Clinic in Geriatric Comprehensive Clinic RSCM:

Development of Frailty Prevention Clinic in Geriatric Comprehensive Clinic RSCM: The Role of Resistance Training as Sarcopenia and Frailty Management Towards Frailty Score, Sarcopenia Score, and Quality of Life

Status

UNKNOWN

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT05511311

Enrollment

220

Registered

2022-08-22

Start date

2022-01-01

Completion date

2022-11-30

Last updated

2022-08-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Frailty, Resistance Training, Sarcopenia

Keywords

frailty, sarcopenia, elderly, resistance training

Brief summary

There is an increasing number of elderly population, not only in Indonesia, but also in the world. With increasing of age, there is also an increasing number of elderly with sarcopenia and frailty. Both of the diseases can lead to dependency, decrease quality of life, and morbidity. Besides nutrition, physical activity, especially resistance training is proven to be beneficial in improving sarcopenia and frailty condition. Currently in Cipto Mangunkusumo National Hospital (RSCM), there is no comprehensive frailty prevention clinic in the geriatric inpatient clinics. This research can be the base of frailty and sarcopenia treatment in RSCM.

Interventions

PROCEDUREResistance Training

Resistance training developed by the researcher (SCR-RSCM) for 12 weeks

PROCEDUREStandard Therapy

Standard therapy for 12 weeks

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

60 Years to No maximum

Healthy volunteers

Yes

Inclusion criteria

* Patients 60 years old or orlder * Categorized as Pre-frail or Frail based on FRAIL criteria * Is not in routine physical activity in the past 3 months * Succeeded Mini Physical Performance Test with score 11 or more

Exclusion criteria

* Cognitive Disturbance (Abbreviated Mental Test \< 8) * Not consenting to join the trial

Design outcomes

Primary

Measure	Time frame	Description
Frailty Status	12 weeks	The FRAIL scale includes 5 components: Fatigue, Resistance, Ambulation, Illness, and Loss of weight (10). Frail scale scores range from 0-5 (i.e., 1 point for each component; 0=best to 5=worst) and represent frail (3-5), pre-frail (1-2), and robust (0) health status
Sarcopenia Status	12 weeks	Measured using: * BIA: \<7.0 kg/m2 in men and \<5.7 kg/m2 in women * Five times sit to stand: ≥12 seconds * Hand-grip strength: \<28 kg for men and \<18 kg for women
Walking Speed	12 weeks	\<1.0 m/s
Patient's Quality of Life	12 weeks	Measured by EQ-5D: ranging from 0 ('worst imaginable health') to 100 ('best imaginable health')

Secondary

Measure	Time frame	Description
Prevalence of Frailty	12 weeks	The FRAIL scale includes 5 components: Fatigue, Resistance, Ambulation, Illness, and Loss of weight (10). Frail scale scores range from 0-5 (i.e., 1 point for each component; 0=best to 5=worst) and represent frail (3-5), pre-frail (1-2), and robust (0) health status
Prevalence of Sarcopenia	12 weeks	Measured using: * BIA: \<7.0 kg/m2 in men and \<5.7 kg/m2 in women * Five times sit to stand: ≥12 seconds * Hand-grip strength: \<28 kg for men and \<18 kg for women

Countries

Indonesia

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026